Barclays Raises Stryker (NYSE:SYK) Price Target to $443.00

Stryker (NYSE:SYK) had its target price upped by equities research analysts at Barclays from $418.00 to $443.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the medical technology company’s stock. Barclays‘s price objective suggests a potential upside of 13.18% from the company’s current price.

A number of other analysts have also recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $442.00 price target on shares of Stryker in a research report on Wednesday, January 29th. JPMorgan Chase & Co. boosted their target price on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Evercore ISI upped their target price on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Wells Fargo & Company boosted their price objective on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Finally, Royal Bank of Canada raised their target price on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average price target of $420.68.

Stryker Stock Performance

Shares of SYK stock opened at $391.42 on Monday. The firm has a market cap of $149.22 billion, a P/E ratio of 50.44, a PEG ratio of 2.98 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The stock’s 50-day moving average is $377.23 and its two-hundred day moving average is $364.97.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the firm earned $3.46 EPS. Analysts predict that Stryker will post 13.49 earnings per share for the current fiscal year.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 5.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Stryker

Several large investors have recently made changes to their positions in the stock. J. W. Coons Advisors LLC lifted its holdings in Stryker by 0.7% during the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company’s stock valued at $1,315,000 after purchasing an additional 26 shares during the last quarter. Opal Wealth Advisors LLC increased its position in Stryker by 1.6% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company’s stock worth $654,000 after acquiring an additional 28 shares during the period. Lindbrook Capital LLC raised its stake in Stryker by 2.0% in the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company’s stock worth $507,000 after purchasing an additional 28 shares in the last quarter. Alhambra Investment Management LLC boosted its holdings in Stryker by 1.5% in the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock valued at $719,000 after purchasing an additional 29 shares during the period. Finally, JFS Wealth Advisors LLC grew its position in shares of Stryker by 4.4% during the 4th quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company’s stock worth $247,000 after purchasing an additional 29 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.